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TuberculosisA B S T R A C T
Tuberculosis and lung cancer rarely coincide together but have been proven to have a
definitive link. In this case we describe tuberculosis and adenocarcinoma diagnosed
together in the same lobe of the lung. The patient was found to have an epidermal growth
factor receptor exon 19 deletion, which has been shown to have an association with
tuberculosis.
 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) and lung cancer are common diseases that
cause substantial morbidity and mortality worldwide [1].
Although the two rarely occur together, a relationship has
been established between them. A study conducted by the
National Cancer Institute found that patients with pulmonary
TB had increased risk of lung cancer [2] and another esti-
mated a twofold elevation in risk of lung cancer in men with
TB [1]. The coexistence of TB and lung cancer is estimated at
2% [3,4] and typically found in the upper lobes [5]. Here, we
describe a case of TB and adenocarcinoma coexisting in the
same lung lobe.Case report
A 44-year-old African-American male presented to the emer-
gency room with a one-day history of nausea and fever. He
had no history of significant medical ailments and did not
smoke. An initial exam indicated that he was afebrile, had
bloodpressure of 196/111 mmHg, a pulse of 103 beats/min, res-
piratory rate of 18 breaths/min, and an oxygen saturation of
98%. His physical examinationwas normal, with no abnormal-
ities on auscultation of the lungs. Laboratory studies indicated
an elevated white blood cell count of 10.9 · 103 cells/lL (local
control = 3.8–10.7 · 103 cells/lL) with 81.5% neutrophils (local
control = 40–79%). C-reactive protein was also elevated at
4.089 mg/dL (local control < 0.748 mg/dL).
Fig. 1 – Chest X-ray showing a 3.9 cm · 4.5 cm mass in the
right upper lobe with mild fullness of the right hilum
(circled).
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with fullness in the right hilum (Fig. 1). Computer topography
scanning without contrast enhancement showed a soft tissue
mass (Fig. 2) along with a soft tissue lesion in the right hilum
and multiple lytic lesions in the vertebrae, left-humeral head,
and sternum. A bone scan to isolate the lytic lesions was per-
formed using 25 millicurie Technetium-99 medronic acid,
with results showing multiple foci of increased uptake.
Given the location, bronchoscopy was performed to obtain a
tissue biopsy of the right upper lobe mass. This showed inva-
sive adenocarcinoma classified as Stage IV due to distal
metastasis to the bone [6]. Epidermal growth factor receptor
(EGFR) tyrosine kinase domain mutations were then evalu-
ated in exons 18–21, with a mutation subsequently detected
in exon 19. Based on genomic results, he began taking
150 mg erlotinib daily to treat the cancer.
Pooled lung secretions from the surrounding area were
collected and cultured to isolate acid-fast bacilli.
QuantiFERON-TB Gold In-Tube test (QFT-G; Cellestis Limited,Fig. 2 – Computer topography scan of the chest showing a
5.0 cm · 3.2 cm mass in the right upper lobe with spiculated
margins (circled).Carnegie, Victoria, Australia) was negative, however, direct
amplification of rRNA using the Amplified Mycobacterium
Tuberculosis Direct test (MTD; Gen-Probe, San Diego, CA,
USA), returned positive results. The presence of
Mycobacterium tuberculosis was confirmed using the BACTEC
MGIT 960 Mycobacterial Detection System (Becton Dickson
Diagnostic Systems, Sparks, Maryland, United States) based
on susceptibility to isoniazid, rifampin, and ethambutol.
The patient was then placed on 750 mg levofloxacin, 300 mg
isoniazid, 50 mg pyridoxine, 2000 mg pyrazinamide, and
1600 mg ethambutol daily for tuberculosis (TB). This particu-
lar drug regimen was chosen given that rifampin, a first-line
TB treatment [7], reduces erlotinib efficacy [8]. The patient
began taking levofloxacin instead, which has similar efficacy
in patients lacking tolerance for rifampin [7].Discussion
Pathogenesis of coexisting TB and lung cancer remains
unclear. One hypothesis suggests that the tumor arises from
a previous TB lesion called a scar cancer [4]. Additionally, TB
may cause sustained inflammation leading to fibrosis, scar-
ring, and host-tissue damage [1]. The fibrosis from the old TB
lesionmay cause lymphostasis, enhancing carcinogen deposi-
tion in the area [4]. Given the distal metastasis found in this
patient,we felt that surgerywasnot appropriate. Thediagnosis
of scar cancer is typically made following tumor resection [5],
so we were unable to determine if this was indeed the case.
There are many other theories concerning the relationship
between TB and lung cancer. One is that TBmycobacterial cell
wall components may induce nitric oxide production and
reactive oxygen species, both implicated in carcinogenesis
[9]. Another suggests that carcinoma may reactivate TB [5].
We were unable to determine disease chronology in this
patient, given that TB and lung cancer were discovered
simultaneously.
There may be a link between pulmonary TB and adenocar-
cinomas displaying the samemutation present in our patient.
Data show that patients with old TB lesions have a statisti-
cally significant association with the EGFR mutation, specifi-
cally in exon 19, as compared with patients with lung
adenocarcinoma without TB [10]. This same study also
demonstrated that a higher proportion of patients with
EGFR mutations and exon 19 deletion displayed lung cancer
and old TB lesions within the same lobe or the same side of
the lung as compared with patients having cancer and TB
lesions located on opposite sides [10].
One of the most interesting results associated with this
patient was the negative QFT-G. We believe this was a false-
negative result. The high specificity for the test is 96–99%,
however, the sensitivity is 81–89% [11]. Furthermore, our
patient displayed pooled secretions identified as M. tuberculo-
sis by direct amplification of rRNA using an MTD test kit with
a specificity of 98.9% [12]. Carcinomas of the head, neck, and
lung display decreased response to the tuberculin skin test in
patients with TB. These conditions may also decrease produc-
tion of IFNc in the QFT-G assay. Thus, a negative QFT-G result
alone would not be sufficient to exclude a diagnosis of TB in
our patient [11].
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but may be difficult. TB lesions can mask lung cancers,
delaying the diagnosis [4]. Patients who initially present with
active TB and lung cancer have lower survival rates than
those having lung cancer without TB [13]. Surgical resection
for early-stage lung cancer with anti-TB therapy is a poten-
tial treatment, however, there are currently no established
guidelines [3,4]. One suggestion is that newly diagnosed TB
cases be followed up periodically with chest X-ray, bron-
choscopy, and sputum cytology to enable early diagnose of
lung cancer [4].
Although rarely occurring together, TB and adenocarci-
noma have an established connection. Diagnosis of simulta-
neous occurrence is difficult, given that one can mask the
other, however, recognition of the diseases is important and
can impact outcomes and patient treatment options.
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